Pharmaceutical

DFV-890 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval

DFV-890 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Jun 18, 2024 - 04:00
DFV-890 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
Read the original article

Tags:

Previous Article

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval

Next Article

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Tanzania reports a Marburg outbreak, Africa’s second this year

Tanzania reports a Marburg outbreak, Africa’s second th...

Mar 22, 2023

House GOP inquiry over gain-of-function research targets a scientific giant

House GOP inquiry over gain-of-function research target...

Jun 22, 2023

The U.S. hasn’t seen syphilis numbers this high since 1950. Other STD rates are down or flat

The U.S. hasn’t seen syphilis numbers this high since 1...

Jan 30, 2024